These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25173403)

  • 1. Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case.
    Shia J; Stadler ZK; Weiser MR; Vakiani E; Mendelsohn R; Markowitz AJ; Shike M; Boland CR; Klimstra DS
    Fam Cancer; 2015 Mar; 14(1):61-8. PubMed ID: 25173403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of DNA mismatch repair deficient crypts in random colonoscopic biopsies identifies Lynch syndrome patients.
    Brand RE; Dudley B; Karloski E; Das R; Fuhrer K; Pai RK; Pai RK
    Fam Cancer; 2020 Apr; 19(2):169-175. PubMed ID: 31997046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
    Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
    Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair protein status of non-neoplastic uterine and intestinal mucosa in patients with Lynch syndrome and double somatic mismatch repair protein mutations.
    Freitag CE; Chen W; Pearlman R; Hampel H; Stanich PP; Cosgrove CM; Konnick EQ; Pritchard CC; Frankel WL
    Hum Pathol; 2023 Jul; 137():1-9. PubMed ID: 37030500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome.
    Pai RK; Dudley B; Karloski E; Brand RE; O'Callaghan N; Rosty C; Buchanan DD; Jenkins MA; Thibodeau SN; French AJ; Lindor NM; Pai RK
    Mod Pathol; 2018 Oct; 31(10):1608-1618. PubMed ID: 29884888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
    Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
    Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis.
    Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G
    Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
    Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
    Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters.
    Staffa L; Echterdiek F; Nelius N; Benner A; Werft W; Lahrmann B; Grabe N; Schneider M; Tariverdian M; von Knebel Doeberitz M; Bläker H; Kloor M
    PLoS One; 2015; 10(3):e0121980. PubMed ID: 25816162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
    Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyloric gland adenoma in Lynch syndrome.
    Lee SE; Kang SY; Cho J; Lee B; Chang DK; Woo H; Kim JW; Park HY; Do IG; Kim YE; Kushima R; Lauwers GY; Park CK; Kim KM
    Am J Surg Pathol; 2014 Jun; 38(6):784-92. PubMed ID: 24518125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
    Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
    Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.
    González-Acosta M; Marín F; Puliafito B; Bonifaci N; Fernández A; Navarro M; Salvador H; Balaguer F; Iglesias S; Velasco A; Grau Garces E; Moreno V; Gonzalez-Granado LI; Guerra-García P; Ayala R; Florkin B; Kratz C; Ripperger T; Rosenbaum T; Januszkiewicz-Lewandowska D; Azizi AA; Ragab I; Nathrath M; Pander HJ; Lobitz S; Suerink M; Dahan K; Imschweiler T; Demirsoy U; Brunet J; Lázaro C; Rueda D; Wimmer K; Capellá G; Pineda M
    J Med Genet; 2020 Apr; 57(4):269-273. PubMed ID: 31494577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
    Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.